Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2019063791) INHIBITOR INHIBITING THE EXPRESSION OF NFAT5
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2019/063791 International Application No.: PCT/EP2018/076462
Publication Date: 04.04.2019 International Filing Date: 28.09.2018
IPC:
C12N 15/113 (2010.01) ,A61K 31/7088 (2006.01)
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
N
MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15
Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09
Recombinant DNA-technology
11
DNA or RNA fragments; Modified forms thereof
113
Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
70
Carbohydrates; Sugars; Derivatives thereof
7088
Compounds having three or more nucleosides or nucleotides
Applicants:
SECARNA PHARMACEUTICALS GMBH & CO. KG [DE/DE]; Bismarckstr. 7 35037 Marburg, DE
Inventors:
JASCHINSKI, Frank; DE
SCHIRDUAN, Ksenija; DE
MICHEL, Sven; DE
Agent:
JANSEN, C.M.; NL
Priority Data:
17193805.328.09.2017EP
Title (EN) INHIBITOR INHIBITING THE EXPRESSION OF NFAT5
(FR) INHIBITEUR INHIBANT L'EXPRESSION DE NFAT5
Abstract:
(EN) The present invention refers to an inhibitor consisting of oligonucleotides comprising to 25 nucleotides, wherein at least one of the nucleotides is modified, and the oligonucleotide hybridizes with a nucleic acid sequence of NFAT5 of SEQ ID NO.1, wherein the oligonucleotide inhibits at least 50 % of the NFAT5 expression. The invention is further directed to a pharmaceutical composition comprising such oligonucleotide.
(FR) La présente invention concerne un inhibiteur constitué d'oligonuclotides comprenant de 10 à 25 nucléotides, au moins l'un desdits nucléotides étant modifié, et l'oligonucléotide s'hybridant avec une séquence d'acide nucléique de NFAT5 de SEQ ID NO.1, l'oligonucléotide inhibant au moins 50 % de l'expression de NFAT5. L'invention concerne en outre une composition pharmaceutique comprenant un tel oligonucléotide.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)